ionispharma.com - IONS EV/Sales Multiple

Official company branding of Ionis Pharmaceuticals, Inc. (IONS)

The complexity of developing drugs for the heart and brain is evident in the price-to-sales multiple dynamics, where the metric stands at 5024.74. Ionis Pharmaceuticals (IONS) minimizes risks through alliances with industry behemoths. The asset's stability is guaranteed by the non-cyclical nature of biotech and its independence from macroeconomic factors. Growing demand for orphan drugs is expanding sales markets, ensuring the long-term resilience of the business.

Ionis (IONS) EV/Sales Multiple: for the period 11/23/2025 - 11/20/2026

Financial and market metric breakdowns for Ionis (IONS)

Fundamental company valuation:IONS (Ionis Pharmaceuticals)
Mass-produced product of ionispharma.com

For the non-cyclical genetic engineering business of Ionis Pharmaceuticals (IONS), this indicator determines the real value of assets by combining market capitalization and net debt, divided by annual sales volume. By analyzing the enterprise value-to-revenue ratio, an investor identifies discrepancies in the market price relative to stable royalty streams. Current price action for the enterprise value-to-revenue ratio confirms the company's high resilience to market shocks.

Competitor analysis for Ionis Pharmaceuticals

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Repligen Corp - Business Value to Revenue|RNA (Avidity Corp) - EV/Sales Multiple|CRISPR Therapeutics Corp - Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio genedx.com (WGS)|EV/Sales Multiple ultragenyx.com (RARE)|EV/Sales Multiple BEAM (Beam Therapeutics Inc)|Sarepta Therapeutics Inc (SRPT) - Enterprise Value-to-Revenue Multiple|twistbioscience.com - EV/Sales Multiple|10x Genomics, Inc. - Enterprise Value-to-Revenue Coefficient|NTLA (Intellia Corp) - Company Value to Revenue|Company Value to Revenue stoketherapeutics.com|Company Value to Revenue BLFS|Company Value to Revenue Wave Life Sciences Corp (WVE)|EV/Sales Multiple MAZE|Total Company Value-to-Revenue Ratio Sionna Therapeutics Inc|Enterprise Value-to-Revenue Ratio Prime Medicine Corp PRME|tayshagtx.com (TSHA) - Enterprise Value-to-Revenue Multiple|QURE - Enterprise Value-to-Revenue Ratio|MeiraGTx Holdings (MGTX) - Company Value to Revenue|Regenxbio (RGNX) - Enterprise Value-to-Revenue Ratio|SLDB - Total Company Value-to-Revenue Ratio|OCGN (Ocugen Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio PACB|Enterprise Value-to-Revenue Ratio Benitec (BNTC)|Design Therapeutics Inc - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Rocket Pharma RCKT|EV/Sales Multiple 4DMT FDMT|LXEO - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Korro Bio Inc.|EDIT: EV/Sales Multiple|SLN - Total Company Value-to-Revenue Ratio|PRQR (ProQR Therapeutics) - EV/Sales Multiple|codexis.com (CDXS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple SGMO|EV/Sales Multiple Nautilus Biotechnology, Inc. (NAUT)|EV/Sales Multiple MGX (Metagenomi Inc.)|Business Value to Revenue DTIL|Generation Bio Co. - EV/Sales Multiple|BOLD: Enterprise Value-to-Revenue Ratio|XCUR (Exicure, Inc.) - Company Value to Revenue|Company Value to Revenue Ratio IMNN|Enterprise Value-to-Revenue Ratio RXi Pharmaceuticals|mustangbio.com (MBIO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio TransCode (RNAZ)|Bionano Genomics Inc. - Company Value to Revenue Ratio|Applied DNA Sciences - Company Value to Revenue|Total Company Value-to-Revenue Ratio bluebirdbio.com (BLUE)|IPA - Enterprise Value-to-Revenue Ratio|OMGA - EV/Sales Multiple|OMIC (Singular Genomics Systems, Inc.) - Company Value to Revenue|Regulus Therapeutics Inc - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Syros Pharmaceuticals|Company Value to Revenue Telesis Bio (TBIO)|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple